STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] LEAP THERAPEUTICS, INC. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Cypherpunk Technologies Inc. reported that it has expanded its cryptocurrency treasury by purchasing an additional $18 million of Zcash (ZEC) on November 18, 2025. This new purchase totals 29,869.29 ZEC at an average price of $602.63 per ZEC. The company previously acquired 203,775.27 ZEC for approximately $50 million at an average price of $245.37 per ZEC. After the latest transaction, Cypherpunk now holds 233,644.56 ZEC at an overall average cost of $291.04 per ZEC, representing 1.43% ownership of the Zcash network.

Positive
  • None.
Negative
  • None.

Insights

Cypherpunk significantly increases its Zcash exposure, concentrating its crypto treasury in a single asset.

Cypherpunk Technologies has committed substantial capital to Zcash, adding $18,000,000 for 29,869.29 ZEC at an average price of $602.63 per coin. This follows an earlier purchase of 203,775.27 ZEC for about $50,000,000 at $245.37 per ZEC. Together, these transactions bring total holdings to 233,644.56 ZEC at an aggregate average cost of $291.04 per ZEC.

By reaching 1.43% ownership of the Zcash network, the company is taking a concentrated position in a single cryptocurrency rather than a diversified basket of digital assets. This ties part of its financial profile directly to the market value, liquidity, and regulatory environment surrounding Zcash. The higher average price of the latest tranche versus the initial purchase also means subsequent performance will be more sensitive to price moves around and above the $602.63 level.

The announcement frames these actions as completed purchases rather than future plans, so the immediate effect is a shift in the asset mix on the balance sheet toward ZEC. Subsequent company filings that include updated financial statements will clarify how large this Zcash position is relative to total assets and equity and how any market value changes are reflected in reported results.

false 0001509745 0001509745 2025-11-18 2025-11-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 18, 2025

 

 

 

 

Cypherpunk Technologies Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-37990   27-4412575
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (I.R.S. Employer
Identification No.)

 

47 Thorndike Street, Suite B1-1
Cambridge, MA 02141

(Address of Principal Executive Office) (Zip Code)

 

(617714-0360

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: 

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   CYPH   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On November 18, 2025, Cypherpunk Technologies Inc. (f./k/a Leap Therapeutics, Inc.), a Delaware corporation (the “Company”) issued a press release announcing the Company has purchased an additional $18 million of Zcash (“ZEC”). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Item 7.01, including Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 8.01 Other Information.

 

As disclosed above, on November 18, 2025, the Company issued a press release announcing it has purchased an additional 29,869.29 ZEC, for $18 million, at an average purchase price of $602.63 per ZEC. The Company previously disclosed in a Current Report on Form 8-K filed November 12, 2025 its initial acquisition totaling 203,775.27 ZEC, purchased for approximately $50 million, at an average purchase price of $245.37 per ZEC. Now, with the new acquisition, the Company’s total ZEC holdings stand at 233,644.56, at an average price of $291.04, bringing the Company’s total Zcash network ownership to 1.43%.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.  Description
99.1  Press Release of the Company, dated November 18, 2025.
104  Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CYPHERPUNK TECHNOLOGIES INC.
   
Date: November 18, 2025 /s/ Douglas E. Onsi
  Douglas E. Onsi
  President & CEO

 

 

 

 

FAQ

What did Cypherpunk Technologies Inc. (LPTX) announce in this 8-K?

Cypherpunk Technologies Inc. announced that it purchased an additional $18 million of Zcash (ZEC), expanding its cryptocurrency holdings and updating investors on its total Zcash position.

How much Zcash did Cypherpunk Technologies buy in the latest transaction?

In the latest transaction, Cypherpunk Technologies bought 29,869.29 ZEC for $18 million, at an average purchase price of $602.63 per ZEC.

What are Cypherpunk Technologies Inc.'s total Zcash (ZEC) holdings now?

After the new purchase, Cypherpunk Technologies holds a total of 233,644.56 ZEC at an overall average cost of $291.04 per ZEC.

How much has Cypherpunk Technologies spent in total on Zcash so far?

Cypherpunk Technologies has disclosed two Zcash purchases: about $50 million for 203,775.27 ZEC initially and $18 million for 29,869.29 ZEC in the latest transaction.

What percentage of the Zcash network does Cypherpunk Technologies own?

The company reports that its Zcash holdings now represent 1.43% of the overall Zcash network.

Is the Zcash purchase information in this 8-K considered filed or furnished?

The Zcash purchase details in Item 7.01 and Exhibit 99.1 are being furnished, not filed, and are not subject to Section 18 liabilities or automatically incorporated into other filings.

What exhibit accompanies Cypherpunk Technologies Inc.'s 8-K about Zcash?

The 8-K includes Exhibit 99.1, which is a press release dated November 18, 2025, and Exhibit 104, the cover page interactive data file embedded in the Inline XBRL document.
Leap Therapeutic

NASDAQ:LPTX

LPTX Rankings

LPTX Latest News

LPTX Latest SEC Filings

LPTX Stock Data

116.14M
49.89M
16.2%
22.06%
3.96%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE